Pulmonary hypertension (PHT) is an oPAP ≥25 mmHg as assessed by right heart catheterization
at rest. It is divided into 5 groups according to its etiology and mechanism. The first group
is patients with pulmonary arterial hypertension due to various reasons (drugs, connective
tissue diseases, etc.). Group 2 is classified as left heart failure, group 3 is due to
chronic lung disease and hypoxemia, group 4 is due to pulmonary arterial obstruction (most
commonly CTEPH), and group 5 is patients with pulmonary hypertension due to multifactorial
In the pathophysiology, pulmonary hypertension occurs when the balance is...
This local, prospective, non-interventional, multi-center study includes patients treated
with Riociguat for inoperable CTEPH(Chronic thromboembolic pulmonary hypertension)/
persistent or recurrent CTEPH after surgical treatment. It is planned to include a total of
400 patients (valid for safety analysis). This study is performed as an all-case
investigation. The treatment of Riociguat is performed based on the product label in Japan.
The standard observation period is 12 months from the 1st treatment of Riociguat. Safety and
effectiveness are evaluated at 4th and 12th month. In addition, the extension observation is
carried out once...
The purpose of this study is to investigate the extent to which diet and exercise may improve
PAH through the modulation of insulin sensitivity. The central hypothesis is that
dysregulated glucose metabolism elicits a response in PAH patients that can be modified by
exercise and diet, thereby leading to improvements in pulmonary vascular disease.
It is recognized that patients with various forms of heart and lung disease exhibit varying
degrees of pulmonary hypertension, pulmonary vascular remodeling, and right ventricular
dysfunction. The genetic, molecular, and cellular processes driving these phenomena are not
well understood. Rapid advances in high throughput omic methodology, combined with powerful
bioinformatics and network biology capability, have created the opportunity to conduct
studies that broadly search for homologies and differences across the spectrum of disease
states associated with pulmonary hypertension, and determinants of the spectrum of right
The study will test the ability a novel wearable sensor based on a smartphone app (Precordior
CardioSignal app) in combination with a sensor device (Suunto Movesense sensor) to
non-invasively measure cardiac motion and function.
This study was designed to evaluate the safety, tolerability, pharmacodynamics and
pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg,
1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to less than 18 years with pulmonary
arterial hypertension (PAH) group 1. The study design consisted of a main study part followed
by an optional long-term extension part. The main treatment period consisted of two phases:
titration phase up to 8 weeks and a maintenance phase up to 16 weeks.
The SAPPHIRE clinical trial seeks to establish the efficacy and safety of repeated monthly
dosing of autologous EPCs transfected with human eNOS (heNOS) in patients with symptomatic
severe PAH on available PAH-targeted medical therapy.
'The TOP Study' is a prospective cohort study whose main objective is to develop better
prognostic biomarkers and identify children at risk of adverse thrombotic outcomes very early
in the course after an initial venous thromboembolic events (VTE). The study will compare
biomarkers in children that develop poor VTE outcomes (such as recurrence, postthrombotic
syndrome and post PE impairment ) after an initial VTE with those that do not develop such
The investigators are testing whether the addition of Pulmonary Hypertension-related
biomarkers, measured across the pulmonary circulation, to the standard hemodynamic evaluation
for Pulmonary Hypertension will lead to more informed choices of Pulmonary Hypertension
therapy and improved patient outcomes.
The objective of this study is to assess the safety, performance and initial effectiveness of
the TIVUS™ System when used for pulmonary artery denervation through subjective and objective
change in clinical parameters and haemodynamic evaluation. This is a prospective,
multi-center, non-randomized, open-label clinical trail. The study will be conducted in up to
4 centers and will recruit up to 15 patients diagnosed with PAH, functional class III who
have stable PAH on a stable drug regimen of two pulmonary arterial hypertension specific